The 2021 European Society of Cardiology (ESC) guidelines for the diagnosis and treatment of acute and chronic heart failure advocate a regimen including an angiotensin-converting enzyme inhibitor or angiotensin receptor neprilysin inhibitor, a beta-blocker, a mineralocorticoid receptor antagonist, and a sodium-glucose co-transporter-2 (SGLT2) inhibitor to reduce mortality and hospitalization [13]. The gene discussed is ACE; the disease is congestive heart failure.